Previous 10 | Next 10 |
Presentation Times and Weblinks Released for Over 35 Presenting Companies Wednesday and Thursday, November 9-10, 2022 NEW YORK, NY / ACCESSWIRE / November 8, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day November Micro-Cap Co...
Dr. Neylan has more than 20 years of experience in the development of biologic treatments from pre-clinical to post-marketing trials across a broad range of therapeutic areas, including specialty and rare diseases Prior to joining industry, Dr. Neylan spent 12 years in academic medici...
NEW YORK and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Sidoti November Virtual Micro-Ca...
Akari Therapeutics ( NASDAQ: AKTX ) said Friday it received a letter from Nasdaq indicating that it is not in compliance with the minimum bid price rule for continued listing. The firm has 180 calendar days, or till Apr. 24, to regain compliance. For further details ...
NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari received a letter from Nasdaq Listing Qualifications indicatin...
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 million Financing supports Akari’s focused pipeline including the Phase 3 Part A clinical trial of nomacopan in severe pediatric hemat...
NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the investor-focused Cantor Oncolog...
Akari Therapeutics ( NASDAQ: AKTX ) plummets 26% premarket on entering into definitive agreements with healthcare-focused institutional investors, including the Akari Executive Chairman of the Board, Dr. Ray Prudo, for the purchase and sale of 15M Akari ADSs at a pur...
NEW YORK and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced it has entered into definitive agreements with healthcare-focused instit...
The shares of U.K.-based Akari Therapeutics ( NASDAQ: AKTX ) reached the highest level since early March on Monday after the company announced changes to its pipeline programs following a reassessment of development timelines and associated costs. Accordingly, Akari ( AK...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...